Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. announced that it has expanded the company’s focus beyond structural heart disease into cardiovascular (CV) disease, starting with atrial fibrillation (AF).

News | Atrial Fibrillation

egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

May 17, 2022

Seamless integration and communication between Philips Ultrasound System - EPIQ CVxi - and Philips Image Guided Therapy System - Azurion - supports efficient fusion-imaging workflow for minimally-invasive treatment of structural heart disease

News | Structural Heart

Philips EchoNavigator Helps Interventional Teams Treat Structural Heart Disease

May 16, 2022 — Philips, a global leader in health technology, announced at EuroPCR (17 - 20 May 2022, Paris, France) the ...

May 16, 2022

Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston Scientific from 1979 to 1999 and a corporate visionary in the minimally invasive surgery industry, passed away peacefully on May 14 just a few days before his 81st birthday.

News | Cardiovascular Business

Boston Scientific Co-founder and Former CEO Passes Away

May 16, 2022 — Boston Scientific announced that Peter M. “Pete” Nicholas, co-founder and former CEO of Boston Scientific ...

May 16, 2022

Key members of the research collaboration: (from left) Prof Roger Foo (Programme Director, ATTRaCT, and Senior Group Leader, GIS), Dr Karin Conde-Knape (Senior Vice President, Global Drug Discovery, Novo Nordisk), Dr Rasmus Rabøl (Corporate Vice President, Global Translation, Novo Nordisk), Dr Natasha Michaelsen (Principal Scientist, Global Translation, Novo Nordisk), Prof Mark Richards (Director, Cardiovascular Research Institute, NUS, and Deputy Director, National University Heart Centre), Prof Derek Haus

News | Heart Failure

A*STAR, NHCS, NUS, and Novo Nordisk to Collaborate on Cardiovascular Disease Research

May 16, 2022 — The Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and Bioinf ...

May 16, 2022

A substantial proportion of patients with COVID and shock had low CI despite preserved EF, suggesting underfilling of the LV, but this proportion was smaller in W2. This difference could not be explained by changes in PEEP between cohorts. This suggests that fluid management strategies may have been more aggressive in W2.

News | Coronavirus (COVID-19)

New Report Published Comparing Hemodynamics of Cardiac Shock in COVID-19 Patients in Pandemic’s First Vs. Second Wave

May 16, 2022 — A new report by a team of cardiologists from the Heart & Vascular Hospital, Hackensack Meridian ...

May 16, 2022

Pump housing and impeller design. (A): (left) Axial flow pump: HeartMate II LVAD (taken from Figure 2 in the HeartMate II left ventricular assist system instructions for use). (B) (right) Centrifugal flow pump: HeartWare assist device (taken from Figure 2 in the HeartWare assist device patient manual).

News | Heart Failure

Study Finds that Concurrent Tricuspid Valve Surgery and Left Ventricular Assist Device Implantation do not Appear to Lower the Incidence of Right Heart Failure

May 16, 2022 — Right heart failure (RHF) continues to be a major source of morbidity and mortality following left ...

May 16, 2022

CRF Meeting Covering Structural Heart Disease Innovations Will Take Place June 8-10

News | TVT

Late-Breaking Science Announced for TVT 2022

May 16, 2022 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature ...

May 16, 2022

Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData

News | Pharmaceuticals

Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

May 13, 2022

Woon-Hong Yeo has developed a smarter stent. Georgia Tech Photo

News | Stents

Georgia Tech Researchers Develop Wireless Implantable Vascular Monitoring System

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

May 13, 2022

The Neurescue device is an FDA-approved device currently in use for patients with severe bleeding which will now be used in a new study to help increase survival rate for those who experience in-hospital cardiac arrests

News | Sudden Cardiac Arrest

MemorialCare Long Beach Medical Center Only Site in Nation to Offer ARISE-Study – New Experimental Treatment for In-Hospital Cardiac Arrest

May 13, 2022 — The MemorialCare Heart & Vascular Institute at Long Beach Medical Center has been designated the only ...

May 13, 2022

Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists

News | Cardiovascular Business

Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

May 12, 2022 — Abbott announced a new partnership with Women as One to launch a new program designed to train more ...

May 12, 2022

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.

Feature | Cardiogenic Shock

Cardiogenic Shock Market Outlook

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032 ...

May 12, 2022

News | Cardiovascular Business

Board Certified Vascular Surgeon Joins NDA Partners as Expert Consultant

May 12, 2022 — NDA Partners General Manager, Eric Fish, announced today that Peter Mackrell, MD, a board certified ...

May 12, 2022

NIH-funded study explains factors linked to increased risk for heart attack or stroke among women who have pregnancy problems related to high blood pressure

News | Womens Cardiovascular Health

Hypertensive Pregnancy Disorders Linked to Future Cardiac Events

May 11, 2022 — Women who experienced complications related to developing high blood pressure, or hypertension, during ...

May 11, 2022

A microscopy picture of muscle cells in a normal heart (left) and muscle cells in a heart of a patient with hypertrophic cardiomyopathy (right). The black areas are single muscle cells. The muscle cells of the hypertrophic cardiomyopathy patient are bigger, and there is more space in between the cells (green), which is filled with scar tissues in the case of patients with hypertrophic cardiomyopathy. The blue indicates where the DNA of the cells can be found. Image courtesy of Anne de Leeuw, copyright Hubre

News | Cardiovascular Clinical Studies

Single Cell RNA Sequencing Uncovers New Mechanisms of Heart Disease

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

May 11, 2022